Clinical Trial

Cephea Early Feasibility Study

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2021-09-20; most recent amendment 2026-07-07.
Status change: Withheld → Recruiting 2022-08-16
Trial Details
NCT Number NCT05061004
Lead Sponsor Abbott Medical Devices
Conditions Mitral Regurgitation
Enrollment 50 participants
Start Date 2022-04-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-08